Cargando…

The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets

BACKGROUND: Methamphetamine use disorder (MUD) poses a considerable public health threat, and its identification remains challenging due to the subjective nature of the current diagnostic system that relies on self-reported symptoms. Recent studies have suggested that MUD patients may have gut dysbi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Linzi, Deng, Zijing, Liu, Wen, Liu, Ruina, Ma, Tao, Zhou, Yifang, Wang, Enhui, Tang, Yanqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543748/
https://www.ncbi.nlm.nih.gov/pubmed/37790913
http://dx.doi.org/10.3389/fcimb.2023.1257073
_version_ 1785114349754384384
author Liu, Linzi
Deng, Zijing
Liu, Wen
Liu, Ruina
Ma, Tao
Zhou, Yifang
Wang, Enhui
Tang, Yanqing
author_facet Liu, Linzi
Deng, Zijing
Liu, Wen
Liu, Ruina
Ma, Tao
Zhou, Yifang
Wang, Enhui
Tang, Yanqing
author_sort Liu, Linzi
collection PubMed
description BACKGROUND: Methamphetamine use disorder (MUD) poses a considerable public health threat, and its identification remains challenging due to the subjective nature of the current diagnostic system that relies on self-reported symptoms. Recent studies have suggested that MUD patients may have gut dysbiosis and that gut microbes may be involved in the pathological process of MUD. We aimed to examine gut dysbiosis among MUD patients and generate a machine-learning model utilizing gut microbiota features to facilitate the identification of MUD patients. METHOD: Fecal samples from 78 MUD patients and 50 sex- and age-matched healthy controls (HCs) were analyzed by 16S rDNA sequencing to identify gut microbial characteristics that could help differentiate MUD patients from HCs. Based on these microbial features, we developed a machine learning model to help identify MUD patients. We also used public data to verify the model; these data were downloaded from a published study conducted in Wuhan, China (with 16 MUD patients and 14 HCs). Furthermore, we explored the gut microbial features of MUD patients within the first three months of withdrawal to identify the withdrawal period of MUD patients based on microbial features. RESULTS: MUD patients exhibited significant gut dysbiosis, including decreased richness and evenness and changes in the abundance of certain microbes, such as Proteobacteria and Firmicutes. Based on the gut microbiota features of MUD patients, we developed a machine learning model that demonstrated exceptional performance with an AUROC of 0.906 for identifying MUD patients. Additionally, when tested using an external and cross-regional dataset, the model achieved an AUROC of 0.830. Moreover, MUD patients within the first three months of withdrawal exhibited specific gut microbiota features, such as the significant enrichment of Actinobacteria. The machine learning model had an AUROC of 0.930 for identifying the withdrawal period of MUD patients. CONCLUSION: In conclusion, the gut microbiota is a promising biomarker for identifying MUD and thus represents a potential approach to improving the identification of MUD patients. Future longitudinal studies are needed to validate these findings.
format Online
Article
Text
id pubmed-10543748
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105437482023-10-03 The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets Liu, Linzi Deng, Zijing Liu, Wen Liu, Ruina Ma, Tao Zhou, Yifang Wang, Enhui Tang, Yanqing Front Cell Infect Microbiol Cellular and Infection Microbiology BACKGROUND: Methamphetamine use disorder (MUD) poses a considerable public health threat, and its identification remains challenging due to the subjective nature of the current diagnostic system that relies on self-reported symptoms. Recent studies have suggested that MUD patients may have gut dysbiosis and that gut microbes may be involved in the pathological process of MUD. We aimed to examine gut dysbiosis among MUD patients and generate a machine-learning model utilizing gut microbiota features to facilitate the identification of MUD patients. METHOD: Fecal samples from 78 MUD patients and 50 sex- and age-matched healthy controls (HCs) were analyzed by 16S rDNA sequencing to identify gut microbial characteristics that could help differentiate MUD patients from HCs. Based on these microbial features, we developed a machine learning model to help identify MUD patients. We also used public data to verify the model; these data were downloaded from a published study conducted in Wuhan, China (with 16 MUD patients and 14 HCs). Furthermore, we explored the gut microbial features of MUD patients within the first three months of withdrawal to identify the withdrawal period of MUD patients based on microbial features. RESULTS: MUD patients exhibited significant gut dysbiosis, including decreased richness and evenness and changes in the abundance of certain microbes, such as Proteobacteria and Firmicutes. Based on the gut microbiota features of MUD patients, we developed a machine learning model that demonstrated exceptional performance with an AUROC of 0.906 for identifying MUD patients. Additionally, when tested using an external and cross-regional dataset, the model achieved an AUROC of 0.830. Moreover, MUD patients within the first three months of withdrawal exhibited specific gut microbiota features, such as the significant enrichment of Actinobacteria. The machine learning model had an AUROC of 0.930 for identifying the withdrawal period of MUD patients. CONCLUSION: In conclusion, the gut microbiota is a promising biomarker for identifying MUD and thus represents a potential approach to improving the identification of MUD patients. Future longitudinal studies are needed to validate these findings. Frontiers Media S.A. 2023-09-18 /pmc/articles/PMC10543748/ /pubmed/37790913 http://dx.doi.org/10.3389/fcimb.2023.1257073 Text en Copyright © 2023 Liu, Deng, Liu, Liu, Ma, Zhou, Wang and Tang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Liu, Linzi
Deng, Zijing
Liu, Wen
Liu, Ruina
Ma, Tao
Zhou, Yifang
Wang, Enhui
Tang, Yanqing
The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets
title The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets
title_full The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets
title_fullStr The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets
title_full_unstemmed The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets
title_short The gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets
title_sort gut microbiota as a potential biomarker for methamphetamine use disorder: evidence from two independent datasets
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543748/
https://www.ncbi.nlm.nih.gov/pubmed/37790913
http://dx.doi.org/10.3389/fcimb.2023.1257073
work_keys_str_mv AT liulinzi thegutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT dengzijing thegutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT liuwen thegutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT liuruina thegutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT matao thegutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT zhouyifang thegutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT wangenhui thegutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT tangyanqing thegutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT liulinzi gutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT dengzijing gutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT liuwen gutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT liuruina gutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT matao gutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT zhouyifang gutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT wangenhui gutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets
AT tangyanqing gutmicrobiotaasapotentialbiomarkerformethamphetamineusedisorderevidencefromtwoindependentdatasets